The DOI matches its Crossref record; 59 of the 60 references it cites were found in a registry or an index.
Adaptive design methods in clinical trials–a review
Open accessAbstract
In recent years, the use of adaptive design methods in clinical research and development based on accrued data has become very popular due to its flexibility and efficiency. Based on adaptations applied, adaptive designs can be classified into three categories: prospective, concurrent (ad hoc), and retrospective adaptive designs. An adaptive design allows modifications made to trial and/or statistical procedures of ongoing clinical trials. However, it is a concern that the actual patient population after the adaptations could deviate from the originally target patient population and consequently the overall type I error (to erroneously claim efficacy for an infective drug) rate may not be controlled. In addition, major adaptations of trial and/or statistical procedures of on-going trials may result in a totally different trial that is unable to address the scientific/medical questions the trial intends to answer. In this article, several commonly considered adaptive designs in clinical trials are reviewed. Impacts of ad hoc adaptations (protocol amendments), challenges in by design (prospective) adaptations, and obstacles of retrospective adaptations are described. Strategies for the use of adaptive design in clinical development of rare diseases are discussed. Some examples concerning the development of Velcade intended for multiple myeloma and non-Hodgkin's lymphoma are given. Practical issues that are commonly encountered when implementing adaptive design methods in clinical trials are also discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This flexibility can improve the efficiency of trials, potentially saving time and resources, and can lead to more ethical studies by minimizing patient exposure to less effective treatments [23].”
From The Work-life Check-ins randomized controlled trial: a leader-based adaptive, semi-structured burnout intervention in primary care clinics (2024) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
O'Quigley, J., Pepe, M., & Fisher, L. (1990) · Biometrics · doi:10.2307/2531628 · Cited by 1,577 · cited 1×
“For adaptive dose finding design, the method of continual re-assessment method (CRM) in conjunction with Bayesian approach is usually considered [34-36].”
Group Sequential Methods with Applications to Clinical Trials
Jennison, C., & Turnbull, B. W. (1999) · Chapman & Hall/CRC eBooks · doi:10.1201/9780367805326 · Cited by 1,336 · cited 3×
“Various stopping boundaries based on different boundary functions for controlling an overall type I error rate are available in the literature (see, e.g., Lan and DeMets, 1987; Wang and Tsiatis, 1987; Rosenberger et al., 2001; Jennison and Turnbull, 2000, 2005; Chow and Chang, 2006).”
Forcing a sequential experiment to be balanced
EFRON, B. (1971) · Biometrika · doi:10.1093/biomet/58.3.403 · Cited by 873 · cited 2×
“Commonly applied adaptive randomization procedures include treatment-adaptive randomization [3,4], covariate-adaptive randomization, and response-adaptive randomization [5,6].”
Adaptive Sample Size Calculations in Group Sequential Trials
Lehmacher, W., & Wassmer, G. (1999) · Biometrics · doi:10.1111/j.0006-341x.1999.01286.x · Cited by 598 · cited 2×
“In recent years, the concept of two-stage adaptive design has led to the development of the adaptive group sequential design (e.g., Cui, Hung, and Wang, 1999; Posch and Bauer, 1999; Lehmacher and Wassmer, 1999; Liu, Proschan, and Pledger, 2002).”
Modification of Sample Size in Group Sequential Clinical Trials
Cui, L., Hung, H. M. J., & Wang, S. (1999) · Biometrics · doi:10.1111/j.0006-341x.1999.00853.x · Cited by 574
Designed Extension of Studies Based on Conditional Power
Proschan, M. A., & Hunsberger, S. A. (1995) · Biometrics · doi:10.2307/2533262 · Cited by 534
Continual Reassessment Method: A Likelihood Approach
O'Quigley, J., & Shen, L. Z. (1996) · Biometrics · doi:10.2307/2532905 · Cited by 382 · cited 1×
“For adaptive dose finding design, the method of continual re-assessment method (CRM) in conjunction with Bayesian approach is usually considered [34-36].”
Approximately Optimal One-Parameter Boundaries for Group Sequential Trials
Wang, S. K., & Tsiatis, A. A. (1987) · Biometrics · doi:10.2307/2531959 · Cited by 341 · cited 1×
“Various stopping boundaries based on different boundary functions for controlling an overall type I error rate are available in the literature (see, e.g., Lan and DeMets, 1987; Wang and Tsiatis, 1987; Rosenberger et al., 2001; Jennison and Turnbull, 2000, 2005; Chow and Chang, 2006).”
Adaptive Designs in Clinical Drug Development—An Executive Summary of the PhRMA Working Group
Gallo, P., Chuang-Stein, C., Dragalin, V., Gaydos, B., Krams, M., & Pinheiro, J. (2006) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543400600614742 · Cited by 323
The Evaluation of Surrogate Endpoints
(2005) · Statistics for Biology and Health · doi:10.1007/b138566 · Cited by 310
Research works printed but not linked: 2
- Whitehead J: Bayesian decision procedures with application to dose-finding studies. International Journal of Pharmaceutical Medicine. 1997, 11: 201-208.
- Wang SJ: Regulatory experience of adaptive designs in well-controlled clinical trials. Presented at Adaptive Designs: Opportunities, Challenges and Scope in Drug Development, Washington, DC. 2006
Cited by
A tutorial on pilot studies: the what, why and how
Thabane, L., Ma, J., Chu, R., Cheng, J., Ismaila, A., Rios, L. P., Robson, R., Thabane, M., Giangregorio, L., & Goldsmith, C. H. (2010) · BMC Medical Research Methodology · doi:10.1186/1471-2288-10-1 · Cited by 3,384
Best care at lower cost: the path to continuously learning health care in America
(2014) · Choice Reviews Online · doi:10.5860/choice.51-3277 · Cited by 1,363
“Advanced statistical methods, including Bayesian analysis, allow for adaptive research designs that can learn as a study advances, making studies more flexible (Chow and Chang, 2008).”
MethodAdaptive designs in clinical trials: why use them, and how to run and report them
Pallmann, P., Bedding, A. W., Choodari-Oskooei, B., Dimairo, M., Flight, L., Hampson, L. V., Holmes, J., Mander, A. P., Odondi, L., Sydes, M. R., et al. (2018) · BMC Medicine · doi:10.1186/s12916-018-1017-7 · Cited by 829
Introduction to Multi-Armed Bandits
Slivkins, A. (2019) · Foundations and Trends® in Machine Learning · doi:10.1561/2200000068 · Cited by 780
The n-of-1 clinical trial: the ultimate strategy for individualizing medicine?
Lillie, E. O., Patay, B., Diamant, J., Issell, B., Topol, E. J., & Schork, N. J. (2011) · Personalized Medicine · doi:10.2217/pme.11.7 · Cited by 706
Metadata
- Authors
- Chow, S.-C., & Chang, M.
- Affiliations
- Duke University (US)
- Takeda Oncology (United States) (US)
- Corresponding author
- Chow, Shein-Chung
- Venue
- Orphanet Journal of Rare Diseases
- Published
- 2008-05-02
- Volume
- 3
- Issue
- 1
- Pages
- 11-11
- ISSN
- 1750-1172 (ISSN-L)
- PMC
- PMC2422839
- OpenAlex
- W2044439361
- Cited by
- 482
- References
- 60
- Citations by year
- 2026: 20 · 2025: 21 · 2024: 25 · 2023: 26 · 2022: 27 · 2021: 27 · 2020: 38 · 2019: 25 · 2018: 26 · 2017: 35 · 2016: 30 · 2015: 34 · 2014: 32 · 2013: 36 · 2012: 36
- FWCI
- 2.11
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/2.0 (tdm)
- Locations
- Orphanet Journal of Rare Diseases (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- National University of Singapore (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- School of Medicine, Duke University
- Takeda Oncology
- Topics
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods and Bayesian Inference
- Keywords
- adaptive trial design, protocol modification, type I error control, rare disease drug development, bortezomib, multiple myeloma, non-Hodgkin lymphoma
- MeSH terms
- Clinical Trials as Topic, Humans, Random Allocation, Research Design, Statistics as Topic, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Rare Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adaptive design methods in clinical trials–a review. https://app.cochat.ai/papers/10.1186/1750-1172-3-11
- The paper
- Chow, S.-C., & Chang, M. (2008). Adaptive design methods in clinical trials–a review. Orphanet Journal of Rare Diseases. https://doi.org/10.1186/1750-1172-3-11
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.



